ong-acting calcium channel blockers are being frequently used for the treatment of hypertension in clinical practice. In particular, amlodipine is one of the most prescribed drugs of long-acting calcium channel blockers. [1] [2] [3] According to the guidelines for the management of hypertension (JSH 2004), the combined treatment of long-acting calcium channel blockers and -blockers is recommended. 4 Betaxolol, a third generation -blocker, is characterized as being long-acting, 1-adrenoceptor selective antagonist with a mild vasodilator effect and has few effects on metabolism of carbohydrates and lipids. [5] [6] [7] [8] It is assumed that calcium channel blockers and -blockers, could have synergistic effects on blood pressure (BP) decrease and prevent a reflex tachycardia caused by the calcium channel blockers.
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Heart rate variability (HRV) indexes are well known prognostic markers for the various cardiovascular disorders, including hypertensive patients. [9] [10] [11] [12] [13] [14] It is likely that the combined treatment of calcium channel blockers and -blockers might have a beneficial effect on cardiac autonomic nervous activity (CANA) assessed by HRV. However, there are no studies to directly compare the dose-up effect of amlodipine with the adding effect of betaxolol on CANA in patients with low dose amlodipine therapy.
Antihypertensive drug therapy might elicit adverse drug reactions and compromise the patient's health-related quality of life (HRQL). 15, 16 Particularly, -blockers might be associated with symptoms such as fatigability and inactivity.
Thus, the purpose of the present study was to evaluate whether betaxolol adding therapy could have better outcomes of CANA assessed by HRV and HRQL evaluated by the questionnaire sheets than amlodipine dose-up therapy in patients with a poor BP control with low dose amlodipine therapy. referred to each hospital as a result of poor BP control, despite the treatment with amlodipine of 2.5 mg to 5.0 mg daily for at least 8 weeks. All of the study patients had systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg. In addition, resting heart rate showed ≥50 beats/min. Exclusion criteria were as follows: (1) the presence of atrial fibrillation; (2) allergic reaction to anti-hypertensive agents; (3) diabetic acidosis; (4) advanced heart blocks; (5) cardiogenic shock; (6) congestive heart failure; (7) pregnancy; or (8) any other acute disorders. Informed consent was obtained from each patient. The study protocol was approved by each institutional review board of participating hospitals.
Study Protocol
This was a multicenter prospective open-labeled blinded endpoints study. Each eligible patient was randomly assigned to 1 of 2 treatment arms of 6 months in a 1:2 ratio, to focus on the combination treatment with betaxolol. Each treatment arm consisted of the amlodipine dose-up group and the betaxolol adding group. The study protocol is summarized in Fig 1. Before the dose-up of amlodipine or adding betaxolol, BP was measured with use of a sphygmomanometer in a sitting position, and 12-lead electrocardiogram (ECG), venous blood sampling for measuring blood chemistries and ambulatory ECG monitoring in a supine position were carried out. From the blood samples, brain natriuretic peptide (BNP, pg/ml), hemoglobinA1c (%), fasting insulin ( U/ml) and fasting blood sugar (mg/dl) were measured by the standard method. HRQL was evaluated using the questionnaire sheets of the SF-8 Japanese version. 15 All of these measurements were repeated before and after each treatment. In the amlodipine dose-up group, amlodipine was gradually titrated by 2.5 mg dose until the patient's BP met an optimal level; systolic BP <130 mmHg and diastolic BP <85 mmHg. In the betaxolol adding group, betaxolol was started at the dose of 2.5 mg and was gradually titrated by 2.5 mg until the above optimal BP levels were achieved. All patients were followed-up for 6 months.
Measurement of HRV
Ambulatory ECG monitoring in a supine position was performed in a dim-lighted, quiet and temperature controlled room by using a Fukuda Denshi Holter system (CardiWalk, SM-60, Tokyo, Japan) and was analyzed by a Fukuda Denshi Holter analyzer (SCM 6000, Dual Holter Workstation system, Fukuda Denshi). Ambulatory ECG monitoring was performed at the almost same time of the day for 30 min before and after the 6-month treatment. All 30 min recording segments were divided into 6 segments of contiguous 5 min intervals. For each 5 min interval, all RR intervals were transferred to a personal computer for the frequency domain analysis of HRV. All RR intervals of 5 min segments were then transformed using a fast Fourier transform to obtain power spectra. The segments that contained any arrhythmias were excluded from the subsequent analysis. The direct current component was excluded in the calculation of the power spectrum to remove the non-harmonic components in the very low-frequency region (<0.04 Hz). 12 Total frequency (TF) spectra (0.04-0.40 Hz), low frequency (LF) spectra (0.04-0.15 Hz) and high frequency (HF) spectra (0.15-0.40 Hz) were obtained. The ratio of LF to HF as well as the ratio of HF to TF were expressed as LF/HF and HF/TF, respectively. [12] [13] [14] Among all segments, maximum and minimum values of LF/HF and HF/TF were discarded and the remaining 3 values were averaged.
HRQL Assessment
All patients answered the self-administered HRQL ques- tionnaires at randomization and after the 6-month treatment to assess both general well-being and specific subjective symptoms. 17 They answered the questionnaires during the clinic visit before any other measurements or examinations were made. To promote quality and avoid missing values, the questionnaires were checked for completeness before the patient left the clinic.
Statistical Analysis
Data are expressed as the mean ± SD. The paired Student's t-test was used to compare data before and after the amlodipine dose-up and the betaxolol adding treatment. The unpaired Student's t-test was also applied to compare data between the 2 groups. Differences were considered significant at p<0.05.
Results

Patient Profile
The present study consisted of 21 patients in the amlodipine dose-up group and 44 patients in the betaxolol adding group as shown in Table 1 . Average values of SV1+RV5 in the 12-lead ECG were similar in both groups. Baseline average amlodipine dosage was comparable between the amlodipine dose-up and the betaxolol adding groups that was 3.6 mg (2.5 mg in 12 patients, 5 mg in 9 patients) and 3.8 mg (2.5 mg in 21 patients, 5 mg in 23 patients), respectively. Most of the patients were in the amlodipine monotherapy. The remaining patients were in a combination treatment with angiotensin II receptor blocker or angiotensin converting enzyme inhibitor. For each group patient, another 3.2±2.7 mg of amlodipine dose-up (thus total dosage of 6.8±8.1 mg) or 3.1±2.7 mg of betaxolol adding was necessary to achieve a good BP control.
Changes in Hemodynamics, HRV and HRQL
The effects of each treatment on hemodynamics and HRV are summarized in Table 2 . Both the amlodipine dose-up and betaxolol adding groups showed significantly and similarly decreased systolic and diastolic BP. In the betaxolol adding group, the heart rate more profoundly decreased than the amlodipine dose-up group. As shown in Table 2 and Figs 2 and 3, the betaxolol adding group showed the significant decrease of LF/HF and reciprocal increase of HF/TP, whereas no significant changes were observed in the amlodipine dose-up group. In addition, the betaxolol adding group showed the more profound salutary effect on HRQL than the amlodipine dose-up group as shown in Figs 4a and 4b. However, the changes in most HRQL questionnaire scores except for role-emotional were not different between the 2 groups, presumably because of a small number of the amlodipine dose-up group (Fig 4c) .
Changes in Blood Chemistries
As shown in Table 3 , both treatment groups did not show detectable changes in most parameters of blood chemistries except for a slight but significant increase of BNP in the betaxolol adding group.
Discussion
The present study showed that the combined treatment of calcium channel blocker and -blocker (the betaxolol adding group) had more beneficial effects on CANA assessed by HRV and HRQL by the questionnaire sheets than the amlodipine dose-up group, whereas the sufficient and similar BP lowering effects were observed in both treatment groups of patients with poorly controlled hypertension, despite taking a low dose of amlodipine.
In the betaxolol adding group, LF/HF decreased and HF/TP increased with a statistical significance, whereas these parameters were not changed in the amlodipine doseup group. These findings are compatible with decreased cardiac sympathetic nervous activity along with a concomitant increase in cardiac vagal nervous activity. Because sympathetic nervous hyperactivity is one of the well known mechanisms of primary (essential) hypertension, 18, 19 the attenuation in cardiac sympathetic activity is necessary for the treatment of poorly controlled hypertensive patients. In addition, the improvement of HRV indexes is presumed as advantageous for prognosis because the decreased HRV indexes are generally considered as being associated with adverse prognosis in cardiovascular disorders. [11] [12] [13] [14] Earlier reports have shown that impaired HRV indexes in patients with hypertension reflect the presence of either left ventricular hypertrophy 9 or coronary artery disease, 10 and that impaired HRV indexes are associated with a poor prognosis in patients with cardiovascular disease. [20] [21] [22] Further prospective studies would be of benefit to determine whether improvements in HRV secondary to the autonomic nervous effect of betaxolol treatment result in more favorable patient outcomes.
Another important finding in the current study is that the administration of -blocker improves the HRQL of poorly controlled hypertensive patients. The betaxolol adding group showed a significantly improved HRQL. The earlier studies on the treatment using -blockers in cardiovascular disease have indicated controversial results on the HRQL. Some reports were concerned with the adverse effect ofblockers on the HRQL in cardiovascular patients, 23 whereas the other showed opposite findings. 22 Although -blockers are reported to show the side-effects of fatigue, depression and sexual dysfunction that lead to impair the HRQL, betaxolol itself or amlodipine-betaxolol combination treatment might specifically maintain the HRQL in the hypertensive patients. Such a favorable finding agrees with a previous report. 24 There were no significant side-effects in both treatment groups. However, BNP significantly increased in the betaxolol adding group after 6 months of treatment. The average BNP value of 62 pg/ml is reported to be not significant in the clinical settings. 25 In addition, the mild increase of BNP by the -blocker treatment was previously reported so that our results of BNP increase by betaxolol are in agreement with the previous study. 26 Moreover, in 15 of 44 patients of the betaxolol adding group, the echocardiographically determined left ventricular dimensions and contraction did not change significantly (data not shown). The metabolism of carbohydrates and lipid profiles was not affected by the betaxolol adding treatment. Because no side-effects were observed in both the amlodipine dose-up and betaxolol adding groups, these treatments appear to be clinically relevant in patients with poorly controlled hypertension, despite taking a low dose amlodipine.
The current study has several limitations. First, we used the frequency domain analysis of HRV, although several time domain HRV indexes are also useful to predict the prognosis of cardiovascular disease. 27 In our study, frequency domain analysis was chosen for the analysis with the reason that sympathetic and parasympathetic nervous activities can be separately assessed. 12 However, because HRV analysis has some limitations on assessing autonomic nervous function, measurements of resting blood catecholamine concentrations and muscle sympathetic nervous activity (eg, in the peroneal nerve) might be necessary. 28 Second, we measured HRV during 30 min in a supine resting condition. 13, 14 CANA during the daily life may be important to evaluate. 29 However, the daily activity could have some variabilities that confound the treatment effect. We carefully selected the supine resting condition with the same recording time of the day before and after the treatment to minimize the diurnal HRV changes. Third, because the number of studied patients was too small and some baseline scores were different between the 2 groups, it might be difficult to conclude that the combination treatment is better than the amlodipine monotherapy. Future studies with a larger number of patients need to be performed. Finally, a large-scale, prospective, randomized study with an additional betaxolol alone group seems to be more appropriate for verifying a clinical benefit of the combination treatment of amlodipine and betaxolol for hypertensive patients. 30 In conclusion, combined treatment of amlodipine and betaxolol is more useful than the amlodipine dose-up therapy in poorly controlled hypertensives, because combined treatment favorably affects CANA assessed by HRV and HRQL evaluated by the questionnaire sheets.
